

## Antibacterial Properties of Clove (*Syzygium aromaticum*) and Tumeric (*Curcuma longa*) Plant Extract On Clinical Isolates

Awe A.S., Awofodu, T., Iyanda, A.A & Chukwuka, I.A

<sup>1</sup> Department of Science Laboratory Technology  
Federal Polytechnic  
Offa, Kwara State, Nigeria

\* Corresponding E-mail: [awesunday5@gmail.com](mailto:awesunday5@gmail.com)

Phone; +2348054940144, +2347065567474

### ABSTRACT

*Momordica charantia* commonly known as Bitter melon or Bitter gourd belongs to the family of *Cucurbitaceae* and commonly grown in the tropical and subtropical regions. It possesses many uses: antimicrobial, antidiabetic, anti helminthic and antioxidant. This present study investigated the antibacterial activity of *Momordica charantia* against *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Bacillus subtilis* using standard methods. The antimicrobial activity was done using agar – well diffusion methods. The result showed that at concentration of 100mg/ml, ethanol and n hexane extracts inhibited the growth of all the tested bacteria, though with varying degree of the susceptibility of the bacterium. The diameter of zones of inhibition obtained ranged from 10 -15 mm to 9 mm and 14 mm for ethanol n hexane extracts respectively. The minimum inhibitory concentration (MIC) value ranged from 30 – 40 mg/ml for both ethanol and n hexane extracts. The minimum bacteriocidal concentration values ranged from 30 - 40 mg/ml for both ethanol and n Hexane extracts. The phytochemical screening result revealed the presence of Tannin, Saponnin, Alkaloids and polyphenol. The liver and the large intestine of the apparently albino rats that were fed with the leaf extract revealed normal histology of the two internal organs. The result obtained in this study support the use of *Momordica charantia* in treating infection and diseases caused by these bacteria.

**Keywords:** Antibacterial, Properties, Clove (*Syzygium aromaticum*), Tumeric (*Curcuma longa*) Plant Extracts, Isolates.

#### iSTEAMS Proceedings Reference Format

Awe A.S., Ganiyu, N.W. & Oluwanishola, R.M. (2019): Antibacterial Properties of Clove (*Syzygium aromaticum*) and Tumeric (*Curcuma longa*) Plant Extract On Clinical Isolates. Proceedings of the 19<sup>th</sup> iSTEAMS Multidisciplinary Conference, The Federal Polytechnic, Offa, Kwara State, Nigeria. 7<sup>th</sup> – 9<sup>th</sup> August, 2019. Pp 91-102. [www.isteam.net/offa2019](http://www.isteam.net/offa2019) - DOI Affix - <https://doi.org/10.22624/AIMS/iSTEAMS-2019/V19N2P11>

### 1. INTRODUCTION

Some plants are used medicinally in different countries and are source of many potent and powerful drugs (Srivastava *et al.*, 1996). Traditional medicine using plant extracts continues to provide health coverage for over 80% of the world's population, especially in the developing world (WHO, 2002). The urgent need to discover new antimicrobial compounds with diverse chemical properties and novel mechanisms of action is on the increase, because of the alarming incidence of new and re-emerging infectious diseases. In addition, bacterial adaptations to antibiotic resistance over the past decades have generate a considerable worldwide public health problem (Anderson, 2003). Plants contain numerous biologically active compounds, many of which have antimicrobial activity (Cowan, 1999). Numerous studies have been conducted with the extracts of various plants, screening antimicrobial activity as well as for the discovery of new antimicrobial compounds (Chah *et al.*, 2006). *Momordica charantia* (Karela) commonly known as bitter gourd, bitter melon or balsam pear is an economically important medicinal plant belonging to the family *Cucurbitaceae*.

Its fruit extract act as anti-diabetic agent in normal and alloxan-diabetic rats (Kolawole *et al.*, 2011). It is indigenous to tropical areas including India, Asia, South America and Nigeria and cultivated throughout South America as food and medicine. Various preparations of *M. charantia* extracts from fruit juice to dried fruit bits have been employed traditionally worldwide, particularly for blood-sugar lowering effects (Welihinda *et al.*, 1986; Raman and Lau, 1996). In addition, it has been reported to exhibit diverse biological activities such as antioxidant, antimicrobial, antiviral, antihepatotoxic and antiulcerogenic activities which are attributed to an array of biologically active plant chemicals including triterpenes, proteins and steroids (Grover and Yadav, 2004). Analyses of phytochemicals from *M. charantia* revealed the presence of active components like momorcharins, momordenol, momordicin, momordicins, momordicinin, momordin, momordolol, charantin, charine, cryptoxanthin, cucurbitins, cucurbitacins, cucurbitanes, cycloartenols, diosgenin, elaeostearic acids, erythrodiol, galacturonicacids, gentisic acid, goyaglycosides, goyasaponins and multiflorenol (Parkash *et al.*, 2002).

In the view of ethnomedical reports, *M. charantia* is being used in folkloric medicine on various ulcers, diabetes and infections (Gurbuz *et al.*, 2000; Scartezzini and Speroni, 2000; Beloin *et al.*, 2005). Although, hundreds of plant species have been screened and tested for antimicrobial properties, the vast majority of the plants have not been adequately screened and evaluated (Gurbuz *et al.*, 2000). Considering the vast potentiality of plants as sources for antimicrobial drugs, the present research aimed to carryout phytochemical screening and evaluates the leaves of *M. charantia* for antimicrobial activity at elevated temperature and under acidic conditions. This present study is aimed to investigate the antibacterial effect of the leaves extracts of *Momordica charantia* against some pathogens.

## 2. MATERIALS AND METHODS

### Materials

Healthy leave of *Momordica charantia*, Weighing balance, Mechanical grinder, Incubator, Oven, Petri-dishes, Sterile filter paper, Rotary evaporator, Cork borer of 7 mm, Test organism (*Escherichia coli* and *Pseudomonas aeruginosa*), Conical flask, Beaker, Polythene bag, Autoclave, Nutrient agar, Mueller hinton agar and Sterile water.

### Methods

#### Sample Collection

A healthy leaves of *Momordica charantia* was collected from the farm land in Omo-Owo area Offa, Kwara State. It was identified botanically and the identification was authenticated by a botanist in the department of Science Laboratory Technology, Offa, Kwara state, Nigeria. The leave was collected and transferred into a polythene bag immediately. The leave was transported to the site of experiment as soon as possible.

#### Sample Preparation

The leave of *Momordica charantia* was cleaned and air dried under the shade at normal room temperature. After drying, the plant material was grounded using mortar and pestle to powder forms and kept in a moisture free, airtight container and kept under room temperature prior to the antibacterial assay.

#### Preparation of Ethanol and N Hexane Extract

100 g of dried powdered sample was soaked in 500 ml of 70% ethanol and n hexane in a different conical flask. Each flask were covered with cotton wool and then wrapped with aluminum foil and shaken vigorously at 5 hours interval for 48 hours at room temperature. After 48 hours, the crude extract was sieved using muslin cloth and whatman no 1 filter paper. The filtrate was evaporated to dryness using rotary evaporator. The dried extract was store in air tight sample bottle until it required.

### Reconstitution Of The Extract

For the antibacterial screening, the crude extract was reconstituted by dissolving 100 and 200mg of the extract in 1 ml of distilled water to obtain a concentration of 100 and 200 mg/ml.

### Sterilization Techniques

**Glass Ware:** All glass ware were washed in soapy water and sterilized in oven at 160°C for 2 hours before use.

**Culture Media:** All media used were prepared according to manufactures specification and sterilized at 121°C for 15 minutes.

### Standardization of The Organisms

The organism was standardized using Mcfarland standard. To make original McFarland tube no 0.5 was prepared by mixing of 1.175% barium chloride ( $\text{BaCl}_2$ ) with 9.95 ml of 1% sulfuric acid ( $\text{H}_2\text{SO}_4$ ) in distilled water in order to estimate bacterial density (Baron *et al.*, 1994). The tube was sealed and was used for comparison of bacterial suspension with standard whenever required.

### Sources Of Microorganism

Pure culture of *Escherichia coli*, *Pseudomonas aeruginosa*, *Bacillus subtilis*, and *Staphylococcus aureus* was obtained from General Hospital Ilorin, Kwara State and Lautech Teaching Hospital Osogbo, Osun State, Nigeria.

### Antimicrobial Activity

The antibacterial activity of crude extract was determined by agar-well diffusion method described by Irobi *et al.*, (1994). All test organism were first grown in nutrient agar for 24hours before used and standardized to 0.5 McFarland standards ( $10^8$  cfu/ml). The organism was inoculate in Mueller hinton agar plate. Sterile cork borer of 6mm was used to make four well in the Mueller hinton agar. 100mg/ml and 200mg/ml of the extract was filled in a separate well, sterile water was used as negative control and filled into third well. Chloramphenicol was used as positive control in the fourth well. All plates were incubated at 37°C for 24 hours in an incubator. After 24 hours of incubation the plate were observed for zone of inhibition.

### Determination Of Minimum Inhibitory Concentration (Mic)

The estimation of MIC of the plant extract was carried out by using the method of Akinpelu and Kolawole (2004). Briefly, 10.0, 20.0, 40.0 and 50.0 mg/ml concentrations of the extract was prepared and introduce into each test tube containing 9 ml of the nutrient broth. 1 ml of the 18 hours standardize organism was also introduced into test tubes containing agar broth and extract. All the test tube was incubated for 24 hours at 37°C. The least concentration of the extract that did not permit any visible growth in the broth was taken as the MIC. The MIC of the extracts was done for each test organisms.

### Determination of Minimum Bactericidal Concentration (Mbc)

The MBC of the plant extracts was determined by the method of Spencer and Spencer (2004). 1 ml of broth were taken from the tubes with no visible growth in the MIC assay and was subcultured on a freshly prepared nutrient agar and later incubated at 37°C for 48 hours. The MBC was taken as the concentration of the extract that did not show any growth on a new set of agar plates.

### Experimental Animals

Eighteen (18) Wister rat of equal sex weighing between 140 -250g were kept in a cage in the botanical garden of Federal Polytechnic Offa, Kwara State, Nigeria.

### Histopathology

Histopathological examination was carried out on the liver and large intestine of the apparently healthy albino rats

### Phytochemical Screening

The extractions and all the qualitative methods have been done according to the most common and reliable methods (Farnsworth, 1996).

### 3. STATISTICAL ANALYSIS

The statistical analysis of the data obtained from antimicrobial activities was carried out using statistical package for social science (SPSS).

### 4. RESULTS

**Table 1: Antimicrobial activities of *Momordica charantia* extract prepared at 100mg/ml**

Test Organisms	Diameter of zones of inhibition in mm			
	Ethanol Extract	n hexane extract	Water	Chloramphenicol
<i>Staphylococcus aureus</i>	10.0 ± 1.0	9.0 ± 0.6	-	13.0 ± 0.2
<i>Bacillus subtilis</i>	14.2 ± 0.4	13.3 ± 0.2	-	12.3 ± 0.6
<i>Escherichia coli</i>	15.1 ± 0.3	14.0 ± 0.4	-	17.9 ± 0.4
<i>Pseudomonas aeruginosa</i>	10.3 ± 1.1	8.2 ± 0.8	-	11.0 ± 0.2

**Key:** (-)=no activity

**Table 2: Antimicrobial activities of *Momordica charantia* extract prepared at 200mg/ml**

Test Organisms	Diameter of zones of inhibition in mm			
	Ethanol Extract	n hexane extract	Water	Chloramphenicol
<i>Staphylococcus aureus</i>	11.2 ± 0.2	9.6 ± 0.4	-	13.3 ± 0.1
<i>Bacillus subtilis</i>	14.9 ± 0.8	12.6 ± 0.7	-	11.3 ± 1.2
<i>Escherichia coli</i>	17.1 ± 0.2	14.5 ± 0.9	-	18.0 ± 0.2
<i>Pseudomonas aureginosa</i>	11.9 ± 0.6	9.4 ± 0.2	-	11.2 ± 0.1

**Key** (-)=no activity

**Table 3: Minimum inhibitory concentration of the leaf extract of *Momordica charantia***

Bacteria	Concentration (mg/ml)							
	Ethanol				n hexane			
	10.0	20.0	30.0	40.0	10.0	20.0	30.0	40.0
<i>S. aureus</i>	+	+	-	-	+	+	-	-
<i>Bacillus subtilis</i>	+	+	-	-	+	+	-	-
<i>Escherichia coli</i>	+	+	-	-	+	+	-	-
<i>Pseudomonas aeruginosa</i>	+	+	+	-	+	+	-	-

**KEY:** (-) = no growth, (+) = growth

**Table 4: Minimum bacteriocidal concentration of the leaf extract of *Momordica charantia***

Bacteria	Concentration (mg/ml)			
	Ethanol		n hexane	
	30.0	40.0	30.0	40.0
<i>S. aureus</i>	+	-	+	-
<i>Bacillus subtilis</i>	-	-	-	-
<i>Escherichia coli</i>	-	-	-	-
<i>Pseudomonas aeruginosa</i>	+	-	+	-

Key: = no growth  
 + = growth


**Table 5: Result of Phytochemical Screening of *Momordica charantia* Leave Extract**

Test	Ethanol	N hexane
Tannin	+	+
Saponnin	+	+
Flavonoid	—	—
Alkaloid	+	+
Glycoside	—	—
Anthraquinones	—	+
Polyphenol	+	+


**KEY**

(-) Absent

(+ ) Present



**Plate 2: Photomicrograph of histological examination of the liver of rat fed with leaf extracts of *Momordica charantia* (a) control rat (b) treated rat both showed normal histological structure of central vein and surrounding hepatocytes**



**Plate 3 : Photomicrograph of the histological examination of large intestine of rat fed with leaf extracts of *Momordica charantia* (a) control rat (b) treated rat both showed regular shaped villi lined by intact and moderately crowned columnar epithelium**

## 5. DISCUSSION

The result for antimicrobial activity of the leave extract of *Momordica charantia* revealed that both ethanol and n hexane extract exhibited varying degree of antimicrobial activities though with ethanol extract demonstrating highest activity against the test organisms. This is an indication that solvent system plays an important role in the solubility of the bioactive component and influence antimicrobial activity. However, the zone of inhibition for ethanol was low when compared with standard drug (Chloramphenicol). Chloramphenicol demonstrated the highest antibacterial activity when compared with both ethanol and n hexane extract. The highest activity was recorded with chloramphenicol because it is a standard antibiotic and it is in a pure state. This work agrees with Sankaranarayanan and Joly (2016) who have clinically demonstrated broad spectrum antimicrobial activity of leaf extracts of *Momordica charantia*

The phytochemical screening of the leaves extract of *Momordica charanta* revealed the presence of Saponins, Tannin, Alkaloid and Polyphenol in both ethanol and n hexane extract which agreed with work of Akinpelu (2004). These compounds are known to be biologically active and therefore aid the antimicrobial activities of *Momordica charanta*. These secondary metabolites exert antibacterial activity through different mechanisms. For instance, tannin have been found to form irreversible complexes with proline rich protein (Shimada 2006) result in the inhibition of cell protein synthesis (Parekh and Chanda 2007) reported that tannins are known to react with protein to provide the typical tanning effect which is important for the treatment of inflamed or ulcerated tissues. Dharmananda (2003) reported that tannins are used for treating disorders such as diarrhea.

These observations therefore support the use of leaves of *Momordica charanta* in curing some ailment caused by the test organisms. Alkaloids were also detected in the leave of *Momordica charanta*, alkaloids are toxic against cells of foreign organisms. These activities have been widely studies for their potential use in the elimination and reduction of human cancer cell lines. The liver of the group of apparently healthy albino rats that were treated with the leaf extract showed normal histological structure of the central vein and surrounding hepatocytes and their large intestine showed regularly shaped villi lined by intact, moderately crowned columnar epithelium. This showed that the leaf extract is not toxic to the internal organs and can be safely administered for therapeutic purposes.

The result of antimicrobial activities and phytochemical screening of *Momordica charantia* leave extract against the test organisms support the claims made by herbalist and local communities on the recommendation of *Momordica charantia* for use in treating many diseases.

## 6. CONCLUSION

The leaves extract of *Momordica charantia* demonstrated antibacterial activities on *Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* and *Bacillus subtilis*. In this study, ethanolic leaves extract exhibited higher zone of inhibition than n hexane extract. Also the plant demonstrated low minimum inhibitory concentration (MIC) values for both ethanol which are very important for evaluation of antimicrobial activity. Therefore, plant could be used as a potential source for the development of an effective antibacterial agents against the tested bacteria. This investigation found that *Momordica charantia* leaves contain Alkaloid, Tannin and Saponnin which could be responsible for the antimicrobial activity observed. Therefore, the extract can be used as antibacterial drug in the treatment of infections and diseases caused by these bacteria.

## 7. RECOMMENDATION

Further pharmacological and clinical studies should be done to understand the mechanism of action and the efficacy of the *Momordica charantia* in treating infection and diseases caused by these bacteria.

## REFERENCES

1. Abdollahi, M.A.B., Zuki, A., Rezaeizadeh., Y.M. Goh. and Noordin, M.M. (2011). Effects of *Momordica charantia* aqueous extract on renal histopathological changes associated with streptozotocin-induced diabetes mellitus type II in neonatal rats. *Journal of Medicinal Plant Research.*, 5(2): 1779-1787.
2. Ahmed, I., E. Adeghate, A.K., Sharma, D.J. Pallot E.A. and Singh, J. (1998). Effects of *Momordica charantia* fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. *Diabetes Research. Clinical Practise.*, 40(7): 145-151.
3. Ahmed, I.M.S., Lakshni, M., Gillet, A., John, I. and Raza, H. (2001). Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic *Momordica charantia* (karela) fruit extract in streptozotocin-induced diabetic rats. *Diabetes Research. Clinical Practise.*, 51(2): 155-161.
4. Akinpelu, D.A. and Kolawole, D.O. (2004). Phytochemical and antimicrobial activity of leaf extract of *Piliostigma thonningii* (Schum.). *Science Focus Journal.* 7 (4):64-70.
5. Anderson D (2003). Persistence of antibiotic resistant bacteria. *Current Microbiology.* 6:452-456.
6. Asiamah, D.M., Verghese, J., Boateng, B., Kanda, L., Shackelford, B. and Walker, L.T. (2011). Chemopreventive potential of bitter melon (*Momordica charantia*) against precancerous lesions in the colon of fisher 344 male rats. *International Journal of Cancer Research.*, 7(4): 36-46.
7. Basch, E., Gabardi, S. and Ulbricht, C. (2003). Bitter melon (*Momordica charantia*): A review of efficacy and safety. *America Journal of Health System Pharmacology.*, 60(3): 356-359.
8. Beloin, N.M. Gbeassor, K. Akpagana, J. Hudson, K. de Soussa, K. Koumaglo, B. and J.T. Arnason, (2005). Ethnomedicinal uses of *Momordica charantia* (Cucurbitaceae) in Togo and relation to its phytochemistry and biological activity. *Journal of Ethnopharmacology.*, 96(2): 49-55.
9. Chah, K.F., Eze, C.A., Emuelosi, C.E. and Esimone, C.O. (2006). Antibacterial and wound healing properties of Methanolic extracts of some Nigerian medicinal plants *Journal of Ethanopharmacology.* 104(8):164-167.
10. Costa, J.G.M., Nascimento, E.M.M. Campos, A.R. and Rodrigues, F.F.G. (2011). Antibacterial activity of *Momordica charantia* (Cucurbitaceae) extracts and fractions. *Journal of Basic Clinical Pharmacology.*, 2(4): 45-51.
11. Cowan, M.M. (1999). Plant Products as Antimicrobial Agents. *Clin. Microbiol. Revise.* 12(4):564-582.
12. Dasgupta, A.A., Mukherjee A.A. and A. Mitra, (2009). Phyto-pharmacology of *Momordica charantia* linn. A review. *Journal of Global Pharmacology Technology.*, 3(2): 7-14.
13. Desai, U.T. and Musmade, A.M. (1998). Pumpkins, Squashes and Gourds. In: *Handbook of Vegetable Science and Technology-Production, Composition, Storage and Processing*, Salunkhe, D.K. and S.S. Kadam (Eds.). Marcel Dekker Inc., New York, pp: 273-297.
14. Dhar, P., Ghosh, S. and Bhattacharyya, D.K. (1999). Dietary effects of conjugated octadecatrienoic fatty acid (9 cis, 11 trans, 13 trans) levels on blood lipids and nonenzymatic *In vitro* lipid peroxidation in rats. *Lipids*, 34(5): 109-114.
15. Dharmananda, S. (2003). Gallnuts and the uses of Tannins in Chinese Medicine. In: *Proceedings of Institute for Traditional Medicine, Portland, Oregon.*
16. Fang, E.F., Yi, C.Z., Zhang, A.B., Bun, T., Ho Ng, J., Wong, W., Liang, P., Juan, X., Ye, Y.S. Chan, S., Ping, W. and Fong, J. (2011). *Momordica Charantia* lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells *in vitro* and *in vivo* *Cancer Prevent Research.* 5(1):109-121.
17. Feng, Z., Li, W.W., Yeung, H.W. Chen S.Z. and Wang, Y.P., (1990). Crystals of  $\alpha$ -momorcharin: A new ribosome-inactivating protein. *Journal of Molecular Biology.*, 214(6): 625-626.
18. Garau, C.E. Cummings B., Phoenix, D.A. and Singh, J. (2003). Beneficial effect and mechanism of action of *Momordica charantia* in the treatment of diabetes mellitus: A mini review. *International. Journal of Diabetes Metabolism.*, 11(8): 46-55.



19. Grover, J.K. and Yadav, S.P. (2004). Pharmacological actions and potential uses of *Momordica charantia*: a review. *Journal of Ethnopharmacology*. 93(3):123-132.
20. Grover, J.K., Rathi, S.S. and Vats, V. (2002). Amelioration of experimental diabetic neuropathy and gastropathy in rats following oral administration of plant (*Eugenia jambolana*, *Mucuna pruriens* and *Tinospora cordifolia*) extracts. *Indian Journal of Biological*., 40(3): 273-276.
21. Gunasekar, M., (2011). Anti-cancer effects of *Momordica charantia* in vitro. Ph.D. Thesis, University of Central Lancashire, Preston.
22. Gurbuz, I., Akyuz, C., Yesilada, E. and Bilge, S. (2000). Anti-ulcerogenic effect of *Momordica charantia* L. fruits on various ulcer models in rats. *Journal of Ethnopharmacology*. 71(2):77-82
23. Huang, H.L., Hong, Y.W., Wong, W.H., Chen, Y.N., Chyuan, J.H. Huang, C.J. and Chao, P.M. (2008). Bitter melon (*Momordica charantia* L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats. *Journal of Nutrition*., 99(5): 230-239.
24. Jayasooriya, A.P. Sakono, M.C., Yukizaki, M., Kawano, K., Yamamoto, Y. and Fukuda, N. (2000). Effects of *Momordica charantia* powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. *Journal of Ethnopharmacology*., 72(3): 331-336
25. Just, M.J., Recio, M.C., Giner, R.M., Cueller, M.J., Manez, S., Bilia, A.R. and Rios, J.L. (1998). Anti-inflammatory activity of unusual lupine saponins from *Bupleurum fruticosum*. *Plant Medicine*. 64(2):404-407.
26. Kolawole, O.T., Abiona, F.E., Kolawole, S.O., Ayankunle, A.A. and Olaniran, O.I. (2011). Effect of *Momordica charantia* fruit extract on normal and alloxan diabetic rats. *International Journal of Pharmacology*. 7(4):532-535.
27. Lee-Huang, S., Huang, P.L. Huang, P.L. Bourinbaiar, A.S. Chen, H.C. and Kung, H.F. (1995). Inhibition of the integrase of Human Immuno-deficiency Virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31. *Proclaim National Academic Science*., 92: 8818-882.
28. Ling, B.G.C., Wang, J., Ya, Zhang, M.X. and Liang, G.W. (2008). Antifeedant activity and active ingredients against *Plutella xylostella* from *Momordica charantia* leaves. *Agricultural Science of China*, 7(6): 1466-1473.
29. Mahmood, A.G.K. Raja, T., Mahmood, M. Gulfranz, and Khanum, A. (2012). Isolation and characterization of antimicrobial activity conferring component(s) from seeds of Bitter melon (*Momordica charantia*). *Journal of Medical Plants Research*., 6(1): 566-573.
30. Malik, Z.A., M. Singh, and Sharma, P.L. (2011). Neuroprotective effect of *Momordica charantia* in global cerebral ischemia and reperfusion induced neuronal damage in diabetic mice. *Journal of Ethnopharmacology*., 133(3): 729-734.
31. Marr, K.L., Mei, X.Y. and Bhattarai, N.K. (2004). Allozyme, morphological and nutritional analysis bearing on the domestication of *Momordica charantia* L. (Cucurbitaceae). *Economy of Botany*., 58(5): 435-455.
32. Munoz, V., Souvain, M.G. Bourdy, J. Callapa, B. and Rojasel, I. (2000). The search for natural bioactive compounds through a multidisciplinary approach in Bolivia. Part II. Antimalarial activity of some plants used by Mosekene Indians. *Journal of Ethnopharmacology*., 69(2): 139-155.
33. Nahas, R. and Moher, M. (2009). Complementary and alternative medicine for the treatment of type 2 diabetes. *Canada Farm Physician*, 55: (3)591-596.
34. Nerurkar, P.V., Johns, L.M., Buesa, G., Kipyakwai L.M. and Volper, E. (2011). *Momordica charantia* (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. *Journal of Neuroinflammation*, 8(2):32-35
35. Omoregbe, R.E., Ikuebe, O.M. and Ihimire I.G. (2008). Antimicrobial activity of some medicinal plants extracts on *Escherichia coli*, *Salmonella paratyphi* and *Shigella dysenteriae*. *Africa Journal of Medicine Science*., 25(2): 373-375.
36. Ooi, C.P., Yassin, Z. and Hamid, T.A. (2010). *Momordica charantia* for type 2 diabetes mellitus. *Cochrane Database System Review*., 10.1002/14651858.CD007845.pub2

37. Parekh, J. and Chanda, S. (2007). *In vitro* antibacterial activity of crude methanol extract of *Woodfordia fruticosa* Kurz flower (Lythaceae). Brazil. *Journal of Microbiology*. 38(3):2.
38. Patel, R., Mahobia, N., Upwar, N., Waseem, N. Talaviya H. and Patel, Z. (2010). Analgesic and antipyretic activities of *Momordica charantia* Linn. fruits. *Journal of Advance. Pharmacology Technology Research.*, 1(3): 415-418.
39. Prakash, A.O. and Mathur, R. (1976). Screening of Indian plants for antifertility activity. *Indian Journal of Experimental Biology.*, 14(6): 623-626
40. Prasad, V., Jain, V., Girish D., and Dorle, A.K. (2006). Wound-healing property of *Momordica charantia* L. fruit powder. *Journal of Herbal Pharmacother.*, 6(3): 105-115.
41. Raman, A. and Lau, C. (1996). Anti-diabetic properties and phytochemistry of *Momordica charantia* L. (*Cucurbitaceae*). *Phytochemical*, 2(2): 349-362.
42. Ray, R.B., Raychoudhuri, A., Steele R. and Nerurkar, P. (2010). Bitter melon (*Momordica charantia*) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. *Cancer Research.*, 70(2): 1925-1931.
43. Reyes, M.E.C., B.H. Gildemacher and G.J. Jansen, (1994). *Momordica* L. In: Plant Resources of South-East Asia: Vegetables, Siemonsma, J.S. and K. Piluek (Eds.). *Pudoc Scientific Publishers, Wageningen, The Netherlands*, pp: 206-210.
44. Rodriguez, D.B., Raymundo, L.C. Lee, T.C., Simpson K.L. and Chichester C.O., (1976). Carotenoid pigment changes in ripening *Momordica charantia* fruits. *Annual Botanical.*, 40(1): 615-624.
45. Roopashree, T.S., Dang, R. Rani, R.H.S. and Narendra, C. (2008). Antibacterial activity of antipsoriatic herbs: *Cassia tora*, *Momordica charantia* and *Calendula officinalis*. *International. Journal of Applied Research. Nation Production.*, 1(2): 20-28.
46. Sankaranarayanan, J. and Jolly, C.I. (1993). Phytochemical, antibacterial and pharmacological investigations on *Momordica charantia* Linn., *Emblica officinalis* Gaertn and *Curcuma longa* Linn. *Industrial. Journal of Pharmacology Science.*, 55: 6-13.
47. Santos, K.K.A., Matias, E.F.F. Sobral-Souza, C.E. Tintino, S.R. and Morais-Braga M.F.B. (2012). Trypanocide, cytotoxic and antifungal activities of *Momordica charantia*. *Pharmacology. Biology.*, 50: 162-166.
48. Semiz, A. and Sen, A. (2007). Antioxidant and chemoprotective properties of *Momordica charantia* L. (bitter melon) fruit extract. *Africa. Journal of Biotechnology.*, 6: 273-277.
49. Sharma, S., Dwivedi, J. and Paliwal, S. (2012). Evaluation of antacid and carminative properties of *Cucumis sativus* under simulated conditions. *Scholars Research Library. Der Pharmacia Lettre* 4(1):234-239.
50. Shih, C.C., Lin, C.H., Lin W.L. and Wu, J.B. (2009). *Momordica charantia* extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. *Journal Of Ethnopharmacology.*, 123: 82-90.
51. Shimada, T. (2006). Salivary proteins as a defense against dietary tannins. *Journal Of Chemical Ecology*. 32(6):1149-1163.
52. Singh, R.K., Dhiman R.C. and Mittal, P.K. (2006). Mosquito larvicidal properties of *Momordica charantia* Linn (Family: *Cucurbitaceae*). *Journal of Vector Borne. Disease.*, 43: 88-91.
53. Srivastava, J., Lambert, J. and Vietmeyer, N. (1996). Medicinal plants: An expanding role in development. World Bank Technical Paper.No.320.Bank
54. Epetimehin, M.F., (2014). Agricultural Insurance in Nigeria and its Economic Impact. Research Gate. <http://www.ssm.com/abstract=1602926> Retrieved 28<sup>th</sup> September, 2017.
55. McKay, A. and Aryeetey (2004). Operationalizing pro-poor growth. A country case study on Ghana: A joint initiative of AFD, BMZ and the World Bank. <http://www.dfdgov.uk/pubs/files/oppreghana.pdf> accessed on September 28, 2017.



56. Nnadi F.N., Chikaire J., Echetama J., Ihenacho R.A., Ummnakwe P.C., and Utazi C.O (2013). Agricultural Insurance: A strategic tool for climate change, adaptation in the agricultural sector. *Net Journal of Agricultural Science*, 1(1) 1-9.
57. Odika V.C (2015). *Government Assisted Schemes: A functional Approach*, Awka, Ezedu printing press.
58. Odo C. (2003). *Introduction to Agricultural Insurance in Nigeria*. Enugu Rainbow Paper Mill Ltd.
59. Omoregbe O., Zivkovic J., and Ademoh F (2014). The role Agriculture in the Economic Development of Nigeria. *European Scientific Joirnal* 10(4) 133-147
60. Wenczeck S., Mclord M., Wiedmaier P., and Biase K. (2016). *A world without hunger is possible – contributions of german development policy*. Bonn 3<sup>rd</sup>. ed.
61. Wenczeck S., Mclord M., Wiedmaier P., and Biase K. (2017). *Inclusive Insurance and Sustainable Development*.
62. World Bank (2008). *World Bank Development Report. Agriculture for Development*, World Bank. Washington DC.